Virtus Biotech Clinical Trials ETF
15 hedge funds and large institutions have $9.33M invested in Virtus Biotech Clinical Trials ETF in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
13% more capital invested
Capital invested by funds: $8.24M → $9.33M (+$1.09M)
1.95% more ownership
Funds ownership: 30.82% → 32.77% (+1.9%)
12% less funds holding
Funds holding: 17 → 15 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$878K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$545K |
| 3 |
LPL Financial
San Diego,
California
|
+$39.5K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$38.5K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$15.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$1.37M |
| 2 |
CCP
Cardan Capital Partners
Denver,
Colorado
|
-$353K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$224K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$50.5K |
| 5 |
AIC
Ameritas Investment Company
Lincoln,
Nebraska
|
-$5K |
BBC Hedge Fund Activity: Q1 2019 in Review
15 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q1 2019, worth a combined $9.33M — up 13% from $8.24M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BBC and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Jane Street, opening a new position worth an estimated $878K. The largest seller was Advisory Services Network, exiting entirely with an estimated $1.37M sold.
- 15 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q1 2019, down from 17 in Q4 2018.
- Funds reported $9.33M of Virtus Biotech Clinical Trials ETF stock for Q1 2019, up 13% quarter-over-quarter.
- 2 funds opened new Virtus Biotech Clinical Trials ETF positions in Q1 2019 and 4 closed out, a net change of -2 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q1 2019 was Jane Street, an estimated $878K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q1 2019 was Advisory Services Network, an estimated $1.37M sold.
Based on aggregated 13F filings for Q1 2019.